loading
전일 마감가:
$3.18
열려 있는:
$3.1112
하루 거래량:
17,299
Relative Volume:
0.02
시가총액:
$3.93M
수익:
-
순이익/손실:
$-16.28M
주가수익비율:
-4.7692
EPS:
-0.65
순현금흐름:
$-13.75M
1주 성능:
-8.28%
1개월 성능:
-26.71%
6개월 성능:
-53.01%
1년 성능:
-48.33%
1일 변동 폭
Value
$3.0801
$3.30
1주일 범위
Value
$2.92
$3.38
52주 변동 폭
Value
$2.92
$17.40

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name
명칭
Pasithea Therapeutics Corp
Name
전화
(818) 422-6172
Name
주소
2110 NARCISSUS CT, VENICE
Name
직원
8
Name
트위터
Name
다음 수익 날짜
2024-08-11
Name
최신 SEC 제출 서류
Name
KTTA's Discussions on Twitter

KTTA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
KTTA 3.10 3.93M 0 -16.28M -13.75M -0.65
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스

pulisher
Nov 21, 2024

Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com

Nov 21, 2024
pulisher
Nov 20, 2024

Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 16, 2024

Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa

Nov 15, 2024
pulisher
Nov 15, 2024

KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 09, 2024

KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia

Nov 09, 2024
pulisher
Nov 04, 2024

Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript

Nov 04, 2024
pulisher
Oct 26, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia

Oct 26, 2024
pulisher
Oct 25, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 20, 2024

pasithea therapeutics corp Earnings dates - RTTNews

Oct 20, 2024
pulisher
Oct 07, 2024

(KTTA) Investment Analysis - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 02, 2024

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com

Oct 02, 2024
pulisher
Sep 30, 2024

Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News

Sep 30, 2024
pulisher
Sep 27, 2024

Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com

Sep 27, 2024
pulisher
Sep 27, 2024

Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News

Sep 27, 2024
pulisher
Sep 27, 2024

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics drops 19% on $5M private placement - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times

Sep 27, 2024
pulisher
Sep 26, 2024

Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR

Sep 26, 2024
pulisher
Sep 26, 2024

Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire

Sep 26, 2024
pulisher
Sep 26, 2024

Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Why XPeng Stock Spiked Higher Today - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL

Sep 26, 2024
pulisher
Sep 26, 2024

KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics : Investor Presentation - Marketscreener.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan

Sep 26, 2024
pulisher
Sep 25, 2024

Factbox-OpenAI key personnel changes - Yahoo! Voices

Sep 25, 2024
pulisher
Sep 25, 2024

Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com

Sep 25, 2024
pulisher
Sep 25, 2024

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 25, 2024
pulisher
Sep 23, 2024

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive

Sep 23, 2024

Pasithea Therapeutics Corp (KTTA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):